- Home
- ATXS vs ZVRA Comparison
ATXS vs ZVRA Comparison
Compare ATXS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- ZVRA
- Stock Information
- Founded
- ATXS 2008
- ZVRA 2006
- Country
- ATXS United States
- ZVRA United States
- Employees
- ATXS N/A
- ZVRA N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- ZVRA Health Care
- Exchange
- ATXS Nasdaq
- ZVRA Nasdaq
- Market Cap
- ATXS 401.2M
- ZVRA 381.0M
- IPO Year
- ATXS 2015
- ZVRA 2015
- Fundamental
- Price
- ATXS $4.04
- ZVRA $7.15
- Analyst Decision
- ATXS Strong Buy
- ZVRA Strong Buy
- Analyst Count
- ATXS 5
- ZVRA 8
- Target Price
- ATXS $26.60
- ZVRA $22.29
- AVG Volume (30 Days)
- ATXS 369.7K
- ZVRA 542.5K
- Earning Date
- ATXS 05-08-2025
- ZVRA 05-07-2025
- Dividend Yield
- ATXS N/A
- ZVRA N/A
- EPS Growth
- ATXS N/A
- ZVRA N/A
- EPS
- ATXS N/A
- ZVRA N/A
- Revenue
- ATXS N/A
- ZVRA $23,612,000.00
- Revenue This Year
- ATXS N/A
- ZVRA $267.44
- Revenue Next Year
- ATXS N/A
- ZVRA $90.10
- P/E Ratio
- ATXS N/A
- ZVRA N/A
- Revenue Growth
- ATXS N/A
- ZVRA N/A
- 52 Week Low
- ATXS $3.56
- ZVRA $4.20
- 52 Week High
- ATXS $12.92
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- ATXS 28.96
- ZVRA 45.68
- Support Level
- ATXS $3.56
- ZVRA $6.77
- Resistance Level
- ATXS $4.39
- ZVRA $7.22
- Average True Range (ATR)
- ATXS 0.42
- ZVRA 0.45
- MACD
- ATXS -0.04
- ZVRA -0.00
- Stochastic Oscillator
- ATXS 22.61
- ZVRA 61.74
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.